Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036981 | 1.00 | LMNA (0.40) | LMNASYKRAB9AWDR5DGAT2 | |
| SCHEMBL24036983 | 0.82 | MAPT (0.38) | DGAT2KAT6AMAPT | |
| SCHEMBL25753682 | 0.82 | MAPT (0.38) | DGAT2KAT6AMAPT | |
| SCHEMBL25623469 | 0.79 | WDR5 (0.31) | WDR5 | |
| SCHEMBL25754244 | 0.79 | LMNA (0.47) | LMNASYKRAB9AWDR5DGAT2 | |
| SCHEMBL24036980 | 0.78 | CYP3A4 (0.42) | MAPT | |
| SCHEMBL25753686 | 0.78 | CYP3A4 (0.42) | MAPT | |
| SCHEMBL24036979 | 0.78 | WDR5 (0.43) | LMNAWDR5 | |
| SCHEMBL24036985 | 0.78 | KCNA5 (0.47) | MAPT | |
| SCHEMBL24037115 | 0.78 | LMNA (0.49) | LMNASYKRAB9ADGAT2KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | LMNA 4654/4885SYK 2287/4885RAB9A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.